![]() CFI is a rate-limiting enzyme in the complement cascade, naturally inhibiting the activity of proteins involved in complement overactivation. Continuous overexpression of CFI in ocular tissue inhibits the complement cascade in the eye and has the potential to halt lesion growth and preserve vision in patients with geographic atrophy secondary to age-related macular degeneration. Adverum designed and evaluated an optimized human CFI cassette using its two proprietary capsids 7m8 and LSV1 enabling IVT delivery. Both capsids demonstrated potent CFI levels in nonhuman primates (NHP), suggesting potential for continuous therapeutic levels of CFI in humans with a potential one-and-done outpatient IVT injection.Īdverum will also deliver data presentations on Ixo-vec (ixoberogene soroparvovec, formerly ADVM-022) currently being evaluated in the Phase 2 LUNA trial in wet age-related macular degeneration (wet AMD). The first of two oral presentations will feature nonclinical data in NHP that support staggered bilateral administration of Ixo-vec in the treatment of wet AMD. Bilateral treatment is an area of unmet need where incidence of neovascularization (nAMD) in the second eye is up to 42% in the first two to three years following diagnosis in the primary eye. ![]() The second oral presentation will focus on identification of dose-dependent inflammation pathways involved in innate and adaptive immune response that are commonly observed in gene therapy. Either A: I started slowing down by then (which I highly thing is the case), or B: air drag became more severe at that time.Poster Presentation: Development of an Intravitreal (IVT) Gene Therapy for Geographic Atrophy (GA) by Overexpressing Complement Factor I (CFI) to Inhibit the Complement Cascadeĭate & Time: Thursday, May 18, 2023, 12:00 pm PDT Poster Presentation: Engineered Melanopsin Mutants for Optogenetic Vision Restoration Poster Presentation: CMC Strategies for AAV Gene Therapies for Highly Prevalent Diseasesĭate & Time: Wednesday, May 17, 2023, 12:00 pm PDT Session: Understanding and Modeling Immune Responses to Gene Therapy and Vaccinesĭate & Time: Thursday, May 18, 2023, 2:00 pm - 2:15 pm PDT Oral Presentation: Identification of Dose-Dependent Immune Landscape Signatures Following Administration of Ixo-vec in Non-Human Primates Session: AAV Vectors: Clinical and Non-Human Primate Studiesĭate & Time: Wednesday, May 17, 2023, 4:15 pm - 4:30 pm PDT Oral Presentation Title: Bilateral Ixo-vec NHP Tolerability and Efficacy Following a Staggered Dosing Interval between Eyes - Gene Therapy nAMD Additionally, a poster presentation will focus on Ixo-vec's evaluation of per cell vector genome biodistribution and mRNA expression in NHP.Īdverum will also present new data in an Optogenetics program, as well as Adverum's adeno-associated virus (AAV) advanced chemistry, manufacturing, and controls (CMC) process development platform for highly prevalent ocular diseases.Īdverum abstracts being presented at ASGCT are as follows The data support the 2x10^11 vg/eye (2E11) and 6x10^10 vg/eye (6E10) doses in combination with enhanced corticosteroid prophylactics regimens in the ongoing Phase 2 LUNA trial. There is probably two reasons why thats there. ![]() Now as you can also see there is a 2 second difference between 0-60 and 0-70. Improving the shifting and getting a short shifter might improve those times greatly. So as you can see there is a about a two second delay between 0-30 and 0-40 0-50 and 0-60. Now thats not correct because the weight was off etc.Īfter that I brought down the weight to 2850lbs and here are the numbers: ![]() I first did a run with 3000lbs as the weight (that weight was setup for when I had a passenger with me the other day). I think those two that are the only ones that really matter. ![]() What was programmed into the Vector FX 2:Ĭar Weight: 2850 lbs (Thats 2617lbs stock, plus me and the tool shed in the trunk)ĬDA: 8.00 Left this one at 8's for now, still need to figure out an accurate CDA I did a run today after installing half of the thermoblock kit. Alright thought I would fill this thread in with some numbers ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |